AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
94,300
Employees94,300
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
94,300
Employees94,300

AZN Key Statistics

Market cap
302.12B
Market cap302.12B
Price-Earnings ratio
30.87
Price-Earnings ratio30.87
Dividend yield
1.70%
Dividend yield1.70%
Average volume
2.62M
Average volume2.62M
High today
$193.97
High today$193.97
Low today
$188.49
Low today$188.49
Open price
$190.46
Open price$190.46
Volume
2.92M
Volume2.92M
52 Week high
$193.97
52 Week high$193.97
52 Week low
$122.48
52 Week low$122.48

Stock Snapshot

AstraZeneca(AZN) stock is priced at $193.10, giving the company a market capitalization of 302.12B. It carries a P/E multiple of 30.87 and pays a dividend yield of 1.7%.

On 2026-02-06, AstraZeneca(AZN) stock traded between a low of $188.49 and a high of $193.97. Shares are currently priced at $193.10, which is +2.4% above the low and -0.4% below the high.

AstraZeneca(AZN) shares are trading with a volume of 2.92M, against a daily average of 2.62M.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $193.97 and a 52-week low of $122.48.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $193.97 and a 52-week low of $122.48.

AZN News

TipRanks 5h
AstraZeneca’s TAPER Study Targets Simpler Severe Asthma Care With Tezepelumab

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is running a Phase 3b trial called TAPER (official title:...

TipRanks 5h
AstraZeneca’s Ondexxya Real-World Bleeding Study Update: What Investors Should Watch

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tool...

TipRanks 1d
AstraZeneca Targets Rare Bone Disorder Data in Russia, Laying Groundwork for Future HPP Opportunities

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is sponsoring an observational study titled “The Effect of...

Analyst ratings

83%

of 29 ratings
Buy
82.8%
Hold
3.4%
Sell
13.8%

More AZN News

TipRanks 2d
AstraZeneca Deepens COPD Insights in Moscow Registry

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Registry Spotlight: Moscow COPD Insights Study Overview: Clinical and dEmographic cha...

TipRanks 3d
AstraZeneca rises 101.5%

AstraZeneca (AZN) is up 101.5%, or $94.16 to $186.93. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try...

TipRanks 3d
AstraZeneca’s AZD4063 Edges Forward in Rare Genetic Cardiomyopathy Trial: What Investors Should Watch

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca Advances Early-Stage Heart Failure Study With AZD4063 Study Overview: Ast...

TipRanks 3d
AstraZeneca Completes Key Drug–Interaction Study for AZD5004, Nudging Pipeline Risk Lower

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tool...

Benzinga 3d
AstraZeneca Responds With Data After FDA Delays Lupus Drug Shot

The US Food and Drug Administration (FDA) on Tuesday issued a complete response letter (CRL) regarding AstraZeneca plc.’s (NYSE:AZN) Biologics License Applicati...

AstraZeneca Responds With Data After FDA Delays Lupus Drug Shot
TipRanks 3d
AstraZeneca, Daiichi Sankyo announce Datroway sBLA granted priority review

Daiichi Sankyo and AstraZeneca’s (AZN) supplemental biologics license application, or sBLA, for Datroway has been accepted and granted Priority Review in the U....

TipRanks 3d
AstraZeneca Faces FDA Setback on Lupus Drug with No Change to Sales Outlook

AstraZeneca Plc (AZN) said the U.S. Food and Drug Administration (FDA) rejected a request for a self-injected version of its lupus drug Saphnelo. The FDA issued...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.